German foreign trade and inward investment group Germany Trade & Invest (GT&I) had representatives at this year's BayBio 2010 conference held on April 7 in San Francisco, California, USA, to highlight opportunities for American companies in Germany, which is the world's second largest market for biotechnology after the USA.
There are more companies operating in the biotech and biomedical sectors there than in any other country in Europe. Revenue in this industry has grown over 40% between 2005 and 2009 and promises to expand in the coming years.
Eastern German "hot bed" for biotech
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze